FDA Clears Vistagen's Refisolone for U.S. Phase 2 Trials
VTGN sits 37% above its 52-week low of $0.43.
Summary
Vistagen Therapeutics has received an FDA "Study May Proceed" letter for its refisolone nasal spray, enabling the company to advance the non-hormonal candidate into U.S. Phase 2 clinical trials for menopausal hot flashes. This positive regulatory milestone is highly significant for a small biotech company, especially one facing substantial doubt about its ability to continue as a going concern and a Nasdaq delisting threat, as highlighted in its recent 10-Q. The news follows promising exploratory Phase 2a results from Mexico, where refisolone demonstrated an 80% reduction in hot flash frequency versus 36% for placebo. Advancing a drug candidate to U.S. Phase 2 provides a critical potential path to future revenue and could materially impact the company's long-term viability and investor sentiment. Traders will closely monitor the initiation and progress of these U.S. trials.
At the time of this announcement, VTGN was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.6M. The 52-week trading range was $0.43 to $5.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.